Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 75.25 GBp
Change Today 0.00 / 0.00%
Volume 0.0
VER On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
OTC US
As of 11:35 AM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

vernalis plc (VER) Snapshot

Open
74.00 GBp
Previous Close
75.25 GBp
Day High
76.00 GBp
Day Low
74.00 GBp
52 Week High
08/13/15 - 85.00 GBp
52 Week Low
08/28/14 - 42.00 GBp
Market Cap
333.7M
Average Volume 10 Days
584.8K
EPS TTM
-0.0060 GBp
Shares Outstanding
443.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERNALIS PLC (VER)

Related News

No related news articles were found.

vernalis plc (VER) Related Businessweek News

No Related Businessweek News Found

vernalis plc (VER) Details

Vernalis plc, a research and development stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Frovatriptan, a selective 5-HT1B/1D receptor agonist for an acute oral treatment of migraine headache and its associated symptoms. The company also has a development and licensing agreement to develop approximately six extended-release liquid formulations of short-acting prescription cough cold products. In addition, it is developing V158866, a fatty acid amide hydrolase inhibitor that is in Phase II proof-of-concept (POC) clinical trial for the treatment of various pain and other CNS disorders; and V81444, an adenosine A2A receptor antagonist, which is in Phase Ib/II POC clinical trial for the treatment of Parkinson’s disease and other neurological disorders. Further, the company is developing AUY922, an intravenous Hsp90 inhibitor for treating a range of cancers in Phase I and Phase II clinical trial; CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukaemia and myelodysplastic syndrome under Phase II trial; V158411 molecule and Servier 1, which are in pre-clinical stage for treating cancer; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc; Genentech Inc; H. Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc; Novartis Pharma AG; Servier Research Group; Taisho Pharmaceutical Co., Ltd.; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.

Founded in 1988

vernalis plc (VER) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 610.0K GBP
Chief Financial Officer and Director
Total Annual Compensation: 417.0K GBP
Compensation as of Fiscal Year 2013.

vernalis plc (VER) Key Developments

Vernalis plc Appoints Ian David Gilham to the Board as Non-Executive Director

Vernalis plc announced that Dr. Ian David Gilham has been appointed to the Board as a Non-Executive Director with effect from 1 July 2015. Dr. Gilham will also serve as Chairman of the company's Remuneration Committee. Dr. Gilham has international experience in the research, development and commercialisation of diagnostic and pharmaceutical products. He is Non-Executive Chairman of a number of UK and European companies including Epistem Holdings Limited, Concepta Diagnostics Limited, Horizon Discovery Group plc, Multiplicom NV, and Biosurfit SA. He also previously worked at GlaxoSmithKline as Vice President - Pharmacogenetics and before that held international general management, marketing business development and R&D positions with Abbott Laboratories, Celltech and Amersham.

Vernalis plc Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 02:30 PM

Vernalis plc Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 02:30 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.

Vernalis plc Appoints Ian David Gilham as Non-Executive Director and Chairman of Remuneration Committee, with Effect from 1 July 2015

Vernalis plc announced that Ian David Gilham has been appointed to the board as a Non-Executive Director with effect from 1 July 2015. Gilham will also serve as chairman of the company's remuneration committee. He also previously worked at GlaxoSmithKline as Vice President at Pharmacogenetics and before that held international general management, marketing business development and R&D positions with Abbott Laboratories, Celltech and Amersham.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VER:LN 75.25 GBp 0.00

VER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.129.90 CHF -0.90
Endo International PLC $78.68 USD -0.322
Impax Laboratories Inc $43.36 USD -0.61
Medicines Co/The $33.07 USD +1.32
UCB SA €67.16 EUR -0.60
View Industry Companies
 

Industry Analysis

VER

Industry Average

Valuation VER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.5x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERNALIS PLC, please visit www.vernalis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.